Abstract: The present invention provides an agent for suppression or interception of the Mailard reaction, which comprises, as the active component, an organogermanium compound represented by formula (1): ##STR1## wherein R.sub.1 to R.sub.3 may be the same or different and each of them represents a hydrogen atom, a lower alkyl group, or a phenyl group; and X represents a hydroxyl group, an O-lower alkyl group, an amino group, or a salt represented by OY (Y is a metal or a basic group-containing compound).Said agent can effectively suppress or intercept the Mailard reaction and has high safety even when administered for a long period of time.

Abstract: The present invention is to provide a highly effective agent for preventing and treating opacity of lens, containing the organic germanium compound represented by the fornula (1); ##STR1## (wherein R1 to R3 represent hydrogen atoms, lower alkyl groups each of which may be the same or different and selected from the group consisting of methyl group, ethyl group, etc., or phenyl groups substituted or unsubstituted; X represents a hydroxyl group, an O-lower alkyl group, an amino group or O.sup.- Y.sup.+ {Y represents a metal such as sodium, potassium, etc., or a compound having a basic group such as lysozyme and basic amino acid, etc.})or (2) a combination of the organic germanium compound and aminoguanidien, or (3) a combination of the organic germanium compound specifically defined above and the specific phenoxazine derivative.

Abstract: The present invention provides (1) an agent for improving the reduced functions of organs caused by inhibited blood circulation, characterized by containing, as an effective component, an organogermanium compound represented by the formula (I) ##STR1## wherein R.sub.1 to R.sub.3 are each a hydrogen atom, a lower alkyl group such as methyl, ethyl or the like which may be the same or different, or a substituted or unsubstituted phenyl group, and X is a hydroxyl group, an O-lower alkyl group, an amino group or O.sup.- Y.sup.+ (Y is a metal such as sodium, potassium or the like, or a basic group-containing compound such as lysozyme, basic amino acid or the like), and (2) a method for improving the reduced functions of organs caused by inhibited blood circulation, characterized by administering, in need of such treatment, an effective amount of an organogermanium compound represented by the above formula (I).

Abstract: The present invention provides (A) an organogermanium compound represented by the general formula (1) ##STR1## wherein X is a halogen atom and R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (2) ##STR2## wherein X and Y are each a halogen atom and R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (3-O), ##STR3## wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (3-S), ##STR4## wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (4-O), ##STR5## wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (4-S), ##STR6## wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, and (B) a process for producing an organogermanium compound represented by each of the formulas (3-O), (3-S), (4-O) and (4-S).

Abstract: The present invention provides (1) a solution for washing and storing separated organs, characterized by containing, as an effective component, an organogermanium compound represented by the formula (I) ##STR1## wherein R.sub.1 to R.sub.3 are each a hydrogen atom, a lower alkyl group such as methyl, ethyl or the like which may be the same or different, or a substituted or unsubstituted phenyl group, and X is a hydroxyl group, an O-lower alkyl group, an amino group or O.sup.- Y.sup.+ (Y is a metal such as sodium, potassium or the like, or a basic group-containing compound such as lysozyme, basic amino acid or the like), and (2) a method for washing and storing separated organs with a solution containing, as an effective component, an organogermanium compound represented by the formula (I).

Abstract: The present invention provides (1) an agent for reducing the nephrotoxicity caused by cyclosporin administration, characterized by containing, as an effective component, an organogermanium compound represented by the formula (I) ##STR1## wherein R.sub.1 to R.sub.3 are each a hydrogen atom, a lower alkyl group such as methyl, ethyl or the like which may be the same or different, or a substituted or unsubstituted phenyl group, and X is a hydroxyl group, an O-lower alkyl group, an amino group or O.sup.- Y.sup.+ (Y is a metal such as sodium, potassium or the like, or a basic group-containing compound such as lysozyme, basic amino acid or the like), and (2) a method for reducing the nephrotoxicity caused by cyclosporin administration, characterized by administering, in need of such treatment, an effective amount of an organogermanium compound represented by the above formula (I).

Abstract: An enzyme, phosphofructokinase is now found to be applicable to detection of a phosphofructokinase-inhibitor possibly present in supravital serum sample or other body fluid sample as collected from human person. When an abnormally high content or potency of the phosphofructokinase-inhibitor is detected in the body fluid samples such as serum by means of the phosphofructokinase, it indicates probability of presence of malignant neoplasms in the donor for the samples, usefully for diagnosis of the neoplasms.